Published in Langenbecks Arch Surg on September 19, 2013
Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med (1955) 4.35
Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol (2004) 2.63
Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med (1994) 2.62
Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab (2004) 2.56
The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract (2009) 2.14
Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer (2008) 2.09
Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab (2000) 2.00
Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol (2003) 1.95
Adrenal cortical carcinoma producing solely mineralocorticoid effect. Am J Med (1955) 1.77
Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol (2006) 1.72
Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol (2002) 1.60
Primary aldosteronism and hypertensive disease. Hypertension (2003) 1.49
Feasibility of laparoscopic adrenalectomy for large adrenal masses. Surg Laparosc Endosc Percutan Tech (2003) 1.40
Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab (2000) 1.36
Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab (2009) 1.30
Minireview: primary aldosteronism--changing concepts in diagnosis and treatment. Endocrinology (2003) 1.27
The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg (2008) 1.23
Primary aldosteronism. N Engl J Med (1998) 1.23
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension (2002) 1.23
Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer (2005) 1.20
Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg (2006) 1.16
A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med (1981) 1.13
Primary hyperparathyroidism associatiated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene. Intern Med (2004) 1.00
Aldosteronomas--state of the art. Surg Clin North Am (2009) 0.98
Outcomes of laparoscopic adrenalectomy for hyperaldosteronism. ANZ J Surg (2007) 0.97
Therapy of adrenocortical cancer: present and future. Am J Cancer Res (2010) 0.96
Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J Rare Dis (2010) 0.91
[Diagnosis of primary hyperaldosteronism]. Med Klin (Munich) (2007) 0.83
Adrenocortical carcinoma with concomitant myelolipoma in a patient with hyperaldosteronism. Arch Pathol Lab Med (2005) 0.82
Primary aldosteronism: results of adrenalectomy for nonsingle adenoma. J Am Coll Surg (2011) 0.81
Primary aldosteronism and malignant adrenocortical neoplasia. Trans Am Clin Climatol Assoc (1975) 0.78
Peritoneal carcinomatosis following laparoscopic resection of an adrenocortical tumor causing primary hyperaldosteronism. Horm Res (1999) 0.78
Pathology of adrenal neoplasms. Minerva Endocrinol (1995) 0.78
[Malignant adrenal cortex carcinoma revealed by an isolated picture of primary hyperaldosteronism]. Arch Mal Coeur Vaiss (1988) 0.78
Primary aldosteronism caused by adrenal cortical carcinoma. Endocrinol Jpn (1982) 0.77
[Aldosterone/renin ratio in the diagnosis of primary aldosteronism]. Medicina (B Aires) (2011) 0.77
Adrenocortical carcinoma manifesting pure primary aldosteronism: a case report and analysis of steroidogenic enzymes. J Endocrinol Invest (2000) 0.77
[Clinical analysis of 149 cases of aldosterone-producing adrenal cortical neoplasms]. Zhonghua Wai Ke Za Zhi (2001) 0.77
[2 cases of primary hyperaldosteronism]. Vutr Boles (1991) 0.76
[Clinical characteristics and surgery outcomes of unilateral nodular adrenal hyperplasia in primary aldosteronism: study of 145 cases]. Zhonghua Yi Xue Za Zhi (2006) 0.76
Aldosterone-producing adrenocortical carcinoma metastases found seven years after adrenalectomy. Int J Urol (1997) 0.76
[Isolated primary hyperaldosteronism caused by adrenocortical carcinoma]. Arch Esp Urol (2000) 0.76
[The prevalence of hypertension after adrenalectomy in patients with primary aldosteronism]. Hinyokika Kiyo (2013) 0.76
A malignant aldosteronoma. Endocr Pract (2004) 0.76
Malignant aldosterone-producing adrenal tumour: reoccurrence with glucocorticoid excess without hyperaldosteronism. Neth J Med (2008) 0.76
Primary aldosteronism due to adrenocortical adenoma with concurrent ileum carcinoid tumor: case report. Endocrine (2010) 0.76
[Malignant aldosteronoma in the differential diagnosis of Conn syndrome]. Acta Med Austriaca (1988) 0.76
Two cases of adrenocortical carcinoma presenting as Conn's syndrome. J Hum Hypertens (2001) 0.76
Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg (2012) 19.78
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06
A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia. Crit Care Med (2006) 3.24
Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int (2010) 1.99
Hepatocyte entry leads to degradation of autoreactive CD8 T cells. Proc Natl Acad Sci U S A (2011) 1.89
Superselective arterial embolisation with a liquid polyvinyl alcohol copolymer in patients with acute gastrointestinal haemorrhage. Eur Radiol (2010) 1.66
Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation (2006) 1.64
Fatal pneumonia caused by Panton-Valentine Leucocidine-positive methicillin-resistant Staphylococcus aureus (PVL-MRSA) transmitted from a healthy donor in living-donor liver transplantation. Transplantation (2006) 1.63
Hypoactive delirium after cardiac surgery as an independent risk factor for prolonged mechanical ventilation. J Cardiothorac Vasc Anesth (2011) 1.61
Intestinal ischemia: current treatment concepts. Langenbecks Arch Surg (2010) 1.60
Irreversible electroporation of a hepatocellular carcinoma lesion adjacent to a transjugular intrahepatic portosystemic shunt stent graft. Korean J Radiol (2013) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys (2007) 1.58
Bile duct damage after cold storage of deceased donor livers predicts biliary complications after liver transplantation. J Hepatol (2013) 1.56
Quantitative phase-contrast tomography of a liquid phantom using a conventional x-ray tube source. Opt Express (2009) 1.55
Quality of life and functional long-term outcome after partial pancreatoduodenectomy: pancreatogastrostomy versus pancreatojejunostomy. Ann Surg Oncol (2005) 1.52
Completion thyroidectomy: effect of timing on clinical complications and oncologic outcome in patients with differentiated thyroid cancer. World J Surg (2012) 1.50
Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant (2007) 1.43
High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice. J Gastroenterol Hepatol (2010) 1.42
Kidney transplant in children weighing less than 15 kg: donor selection and technical considerations. Transplantation (2002) 1.41
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1.40
Pumpless extracorporeal interventional lung assist in patients with acute respiratory distress syndrome: a prospective pilot study. Crit Care (2009) 1.40
Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol (2009) 1.34
The liver: a special case in transplantation tolerance. Semin Liver Dis (2007) 1.33
Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput Biol (2012) 1.32
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther (2007) 1.29
Surgical strategy in aortoesophageal fistulae: endovascular stentgrafts and in situ repair of the aorta with cryopreserved homografts. Ann Surg (2007) 1.29
Tumor detection in the bladder wall with a measurement of abnormal thickness in CT scans. IEEE Trans Biomed Eng (2003) 1.28
Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther (2011) 1.26
Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol (2011) 1.25
mTOR, cancer and transplantation. Am J Transplant (2008) 1.24
Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation (2009) 1.16
Tumor detection by virtual cystoscopy with color mapping of bladder wall thickness. J Urol (2002) 1.16
IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther (2012) 1.14
Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer (2010) 1.12
Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int (2005) 1.11
Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol (2008) 1.10
The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int (2010) 1.10
Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer (2008) 1.10
Surgical treatment of substernal goiter: an analysis of 59 patients. Surg Today (2008) 1.09
Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int (2011) 1.07
Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation (2010) 1.07
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Thyroid metastases of renal cell carcinoma: clinical course in 45 patients undergoing surgery. Assessment of factors affecting patients' survival. Thyroid (2008) 1.04
rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats. Hepatology (2005) 1.04
The biology of CD45 and its use as a therapeutic target. Leuk Lymphoma (2004) 1.04
Gracilis transposition for repair of recurrent anovaginal and rectovaginal fistulas in Crohn's disease. Int J Colorectal Dis (2008) 1.03
Support time-dependent outcome analysis for veno-venous extracorporeal membrane oxygenation. Eur J Cardiothorac Surg (2011) 1.03
Fistula-associated anal adenocarcinoma in Crohn's disease. Inflamm Bowel Dis (2010) 1.02
Minimally invasive direct coronary artery bypass in a child with an occlusion of left main coronary artery after arterial switch operation. Interact Cardiovasc Thorac Surg (2013) 1.02
Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era. Am J Clin Pathol (2005) 1.02
Mesenchymal stem cells can affect solid organ allograft survival. Transplantation (2009) 1.01
Intraabdominal septic complications following bowel resection for Crohn's disease: detrimental influence on long-term outcome. Int J Colorectal Dis (2008) 0.99
Procedures for ethical review for clinical trials within the EU. BMJ (2009) 0.99
Carbon monoxide inhalation rescues mice from fulminant hepatitis through improving hepatic energy metabolism. Shock (2007) 0.98
Calcineurin inhibitor minimization protocols in liver transplantation. Transpl Int (2009) 0.97
Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis. Int J Colorectal Dis (2005) 0.97
Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I). J Transl Med (2011) 0.97
Mesenchymal stem cells as immunomodulators after liver transplantation. Liver Transpl (2009) 0.97
Minimal extracorporeal circulation: an alternative for on-pump and off-pump coronary revascularization. Ann Thorac Surg (2009) 0.96
A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer (2013) 0.96
Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells. Biochim Biophys Acta (2010) 0.95
Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology (2009) 0.94
No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury. Stem Cells (2006) 0.94
ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer (2008) 0.94
Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg (2007) 0.94
Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Mol Cancer Ther (2008) 0.93
Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol (2011) 0.93
Therapeutic potential of bone marrow stem cells for liver diseases. Curr Stem Cell Res Ther (2006) 0.92
Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol Cancer Ther (2007) 0.92
Serial use of an interventional lung assist device and a ventricular assist device. ASAIO J (2010) 0.91
Influence of percutaneous abscess drainage on severe postoperative septic complications in patients with Crohn's disease. Int J Colorectal Dis (2011) 0.91
Automated determination of the center of rotation in tomography data. J Opt Soc Am A Opt Image Sci Vis (2006) 0.91
Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res (2012) 0.90
Single-incision retroperitoneoscopic adrenalectomy and single-incision laparoscopic adrenalectomy. J Endourol (2010) 0.90
Up-regulation of Krüppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha. Mol Cancer Res (2009) 0.90
Regulation of polyamine synthesis in human hepatocytes by hepatotrophic factor augmenter of liver regeneration. Biochem Biophys Res Commun (2006) 0.89
Benefit of Kupffer cell modulation with glycine versus Kupffer cell depletion after liver transplantation in the rat: effects on postischemic reperfusion injury, apoptotic cell death graft regeneration and survival. Transpl Int (2005) 0.89
High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes. Biochem Biophys Res Commun (2006) 0.89
Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg (2009) 0.89
Heart grafts tolerized through third-party multipotent adult progenitor cells can be retransplanted to secondary hosts with no immunosuppression. Stem Cells Transl Med (2013) 0.89
DX5+ NKT cells induce the death of colitis-associated cells: involvement of programmed death ligand-1. Eur J Immunol (2006) 0.88
Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int J Colorectal Dis (2005) 0.88
Different approaches for complete mobilization of the splenic flexure during laparoscopic rectal cancer resection. Int J Colorectal Dis (2012) 0.88
Cardiopulmonary bypass in malignant hyperthermia susceptible patients: a systematic review of published cases. J Thorac Cardiovasc Surg (2011) 0.87
Heme oxygenase-1-derived carbon monoxide stimulates adenosine triphosphate generation in human hepatocyte. Biochem Biophys Res Commun (2005) 0.87
Extracorporeal membrane oxygenation by single-vessel access in adults: advantages and limitations. ASAIO J (2012) 0.86
Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin. Transpl Int (2007) 0.86
Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo. Cancer Biol Ther (2007) 0.86